Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | TEC | P42680 | 1/20 | 0.34 |
| ▸ | TXK | P42681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182745 | 1.00 | NEK2 (0.47) | NEK2ALDH1A1MAPTKMT2ALMNA | |
| Nitrous Acid SCHEMBL13276537 | 0.79 | ROCK2 (0.37) | NEK2ROCK2ROCK1METFGFR1 | |
| Nitrous Acid SCHEMBL13276538 | 0.79 | ROCK2 (0.37) | NEK2ROCK2ROCK1METFGFR1 | |
| SCHEMBL10212416 | 0.78 | ROCK2 (0.39) | NEK2ROCK2ROCK1FGFR1FGFR2 | |
| SCHEMBL560975 | 0.77 | NEK2 (0.77) | NEK2ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL560974 | 0.77 | NEK2 (0.77) | NEK2ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL561253 | 0.77 | ALDH1A1 (0.37) | NEK2ALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL561254 | 0.77 | ALDH1A1 (0.37) | NEK2ALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL29956581 | 0.72 | CHEK1 (0.44) | ALDH1A1MAPTKMT2AKDM4EROCK2 | |
| SCHEMBL182453 | 0.72 | CHEK1 (0.44) | ALDH1A1MAPTKMT2AKDM4EROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422263-B2 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9073939-B2 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-8759341-B2 | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759341-B2 | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2485726-B1 | FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-2485726-B1 | FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-8642595-B2 | Annellated 4-(indazolyl)-1,4-dihydropyridine derivatives and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642595-B2 | Annellated 4-(indazolyl)-1,4-dihydropyridine derivatives and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| EP-2451817-B1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2451817-B1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| EP-2300482-B1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AS c-Met MEDIATORS | Bayer Pharma AG (DE) | 2012-01-04 | — | — | EP | disclosed |
| EP-2300482-B1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AS c-Met MEDIATORS | Bayer Pharma AG (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110172221-A1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172221-A1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-14 | — | — | US | disclosed |
| WO-2011042368-A1 | FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011003604-A1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010094405-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-26 | — | — | WO | disclosed |
| WO-2009149836-A1 | ANNELLATED 4- (INDAZOLYL) -1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172221-A1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | MET, ERBB4, RET | NEK2 827/4885ALDH1A1 323/4885MAPT 2895/4885 |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | MET, RET, ERBB2 | NEK2 1049/4885ALDH1A1 916/4885MAPT 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.